Colby Pharmaceutical Company is developing a drug pipeline containing four small molecule pharma drug candidates targeting cellular pathways producing reactive oxygen species (ROS), including hormones, cytoplasmic oxidase enzymes, signalling proteins and mitochondrial electron transport reactions involved in prostate inflammation and cancer.
Colby Drug Development Pipeline Projected Timelines
Each of Colby’s Oxidative Stress Modulator (OSM) drugs has a novel mechanism of action (MOA) targeting specific hormone-, enzyme-, or other- Oxidative Stress pathways. Colby’s OSM drugs act directly at the cellular metabolic sources of oxygen free radicals (OFR) in prostate and certain other human cells producing hydrogen peroxide, superoxide anions, hydroxyl, and other radicals involved in cell and tissue oxidative damage, inflammation, tumor progression, angiogenesis and metastasis.
Oxidative stress changes and various different tissue OFR damages can drive tissue injury, prostatic inflammation, hyperplasia, and neoplasia. The diseased and cancerous prostate epithelial cells can be therapeutically treated with OSM drugs with little or no significant effect on normal prostate cells.
Therapeutic Targets of OSM Compounds
